Closed · W81XWH-15-DMDRP-TLA · CFDA 12.420 · Discretionary

DoD Duchenne Muscular Dystrophy Translational Leverage Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
October 21, 2015
Close date
1
Expected awards

The verdict

DoD Duchenne Muscular Dystrophy Translational Leverage Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Archived opportunity record

DoD Duchenne Muscular Dystrophy Translational… is closed (last close October 21, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed October 21, 2015

Posted Jun 4 Closes Oct 21

Est. Total Funding

$400,000

Expected Awards

1

Instrument

Grant

Description

The DMDRP Translational Leverage Award (TLA) mechanism is being offered for the first time in FY15. The TLA supports leveraging existing human-based resources in translational research to address high-impact research ideas or unmet needs in at least one FY15 DMDRP Focus Area. Often, resources are not leveraged for maximum use beyond the original source, and as a result, investigators expend time and money to duplicate those resources. This award supports translational research projects leveraging and/or querying existing repositories, registries, and/or clinical trials or clinical studies in order to conduct research in the FY15 DMDRP Focus Areas.Projects may include, but are not limited to, drug and/or device development, novel interventions, resource refinement, database mining, and correlative studies.Leveraging: For the FY15 DMDRP, leveraging involves addressing research questions using existing resources to amplify potential gains in knowledge in the field of DMD, and subsequently making the results or outcomes available for use by others. Outcomes from research funded by this award are expected to provide data and scientific rationale for future research that will impact DMD clinical care.• Human-Based Resources: Examples of human-based resources include, but are not limited to, biorepositories of clinical specimens, imaging repositories, epidemiological datasets, clinical databases, and databases of clinical data and/or metadata.• Biomarker Studies: For projects addressing the FY15 DMDRP Focus Area of “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a biological marker, or biomarker, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.1 For the purpose of this award, biomarker qualification is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.2 Alternatively, biomarker validation refers to the process of ensuring that a biomarker or technology (e.g., imaging) will be accurately and reliably measured through the performance characteristics of a biomarker assay.3 The DMDRP encourages the study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging, etc.). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others.Clinical trials are not supported by this award mechanism.

Catch-all / unrestricted eligibility mark · W81XWH-15-DMDRP-TLA

Grants.gov marks DoD Duchenne Muscular Dystrophy Translational… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507

What to do next

DoD Duchenne Muscular Dystrophy Translational… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants